We should remember we are a VERY) small company (8-10
We should remember we are a VERY) small company (8-10 employees, no revenue and precarious finances) .
We have a good drug, we know it, but FDA still doesn't know it (completely) and neither Government institutions.
Whatever we say does not carry weight. CytoDyn ?? Who ??? Ah, I see, an OTC company with no approved drugs …. Mmmmmm,
So, we should temper our expectations and stop comparing ourselves with GILD and the like. We are not them. Our management is doing way too much with very little.
The way to leverage our advantage is to show Vyrologix works (we all know that). In my opinion we should be better served by trying the "back door". Go full blast in China, Taiwan, Korea, Japan or wherever and demonstrate there that we are for real. We have plenty of patients there, they are under pressure and are reacting at much faster pace than here in the USA (China is already at the right side of their infections curve).
Believe me, the news will be heard by the FDA and in Washington.
Then, we will be [i]that little company that has a drug that works [/i]
My point being: What is happening with out efforts in the Far East ?? We haven't hear anything yet and I am sure something is going on. At the beginning, I though going there was the right think to do knowing how "fast" FDA moves. Hopefully we will hear soon what progress has been made.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...
Continue Reading
Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...
Continue Reading
Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Top 5 Most Recently Viewed Articles
Discovering the Path to Martech Success In today's digital landscape, marketing technology (Martech) is a vital part of any successful business strategy. Organizations face a myriad of challenges in implementing these technologies effectively. Recent research from GNW Consulting sheds light on the factors that differentiate successful Martech initiatives from those that...
Continue Reading
Understanding the Current Situation with Rocket Pharmaceuticals In a significant development for investors involved with Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a class action lawsuit has been initiated. This alert serves as a vital reminder for those who have invested in the company, aiming to clarify your rights and the necessary steps moving forward. Investment...
Continue Reading
Hammond Power Solutions Announces Acquisition of Micron Industries Hammond Power Solutions Inc. (HPS) (TSX: HPS.A) has officially declared its plans to broaden its operations through a major acquisition. The company has reached a definitive agreement to acquire the assets of Micron Industries Corporation, a well-respected name in the electrical manufacturing industry....
Continue Reading
Vantive and IDBS Team Up for Advanced Organ Therapy Innovation In a transformative move for the organ therapy sector, Vantive, a renowned company dedicated to kidney care, has forged a partnership with IDBS. This collaboration aims to revolutionize the digital landscape of vital organ therapy through advanced technology and data management capabilities. Milestone in...
Continue Reading
PSG Strengthens EdTech Landscape with New Investments PSG, a leading growth equity firm, has made a significant move to bolster educational technology by announcing strategic investments in two key software companies. These companies, Verity IQ and Campus Ivy, are focused on improving educational environments. Verity IQ is recognized for its customer relationship...
Continue Reading